{"id":630,"date":"2025-03-24T11:45:00","date_gmt":"2025-03-24T11:45:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=630"},"modified":"2025-03-24T11:55:11","modified_gmt":"2025-03-24T11:55:11","slug":"exenatide-pd3","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/exenatide-pd3\/","title":{"rendered":"Exenatide &#8211; PD3"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"344\" src=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/University_College_London_logo-1024x344.jpg\" alt=\"\" class=\"wp-image-633\" style=\"width:auto;height:400px\" srcset=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/University_College_London_logo-1024x344.jpg 1024w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/University_College_London_logo-300x101.jpg 300w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/University_College_London_logo-768x258.jpg 768w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/University_College_London_logo.jpg 1280w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 3 Trial of exenatide for Parkinson\u2019s disease<\/h2>\n\n\n\n<p>Exenatide-PD3 is a clinical research trial for Parkinson\u2019s disease patients. It is a randomised, double-blind, placebo-controlled, parallel group phase 3 trial that will investigate the potential disease-modifying effects of Exenatide over two years. <br><br>Parkinson&#8217;s disease is the second most common neurodegenerative disease, and its prevalence is increasing. Currently, treatments for Parkinson&#8217;s can only help with the symptoms but they do not have an impact on the progressive nature of the disease. Exenatide is a licensed treatment for patients with type 2 diabetes and has been the subject of multiple phase 3 trials in patients with type 2 diabetes. Laboratory work has shown that Exenatide has beneficial effects on neurons in vitro and could have potential use as a neurodegenerative disease-modifying agent.<br><br>The primary objective of the trial is to compare the effectiveness of exenatide versus placebo over the course of two years. The study will look at clinical features of Parkinson&#8217;s Disease such as motor function, cognitive ability, quality of life, and side effects. If the trial is successful, exenatide could become an important new treatment for Parkinson&#8217;s disease, potentially slowing down the progression of the disease and improving patients&#8217; quality of life.<\/p>\n\n\n<style>.wp-block-kadence-column.kb-section-dir-horizontal > .kt-inside-inner-col > .kt-info-box630_123b79-cd .kt-blocks-info-box-link-wrap{max-width:unset;}.kt-info-box630_123b79-cd .kt-blocks-info-box-link-wrap{padding-top:var(--global-kb-spacing-xs, 1rem);padding-right:var(--global-kb-spacing-xs, 1rem);padding-bottom:var(--global-kb-spacing-xs, 1rem);padding-left:var(--global-kb-spacing-xs, 1rem);}.kt-info-box630_123b79-cd .kadence-info-box-icon-container .kt-info-svg-icon, .kt-info-box630_123b79-cd .kt-info-svg-icon-flip, .kt-info-box630_123b79-cd .kt-blocks-info-box-number{font-size:50px;}.kt-info-box630_123b79-cd .kt-blocks-info-box-media{border-top-width:0px;border-right-width:0px;border-bottom-width:0px;border-left-width:0px;padding-top:10px;padding-right:10px;padding-bottom:10px;padding-left:10px;}.kt-info-box630_123b79-cd .kt-blocks-info-box-media-container{margin-top:0px;margin-right:15px;margin-bottom:0px;margin-left:15px;}.kt-info-box630_123b79-cd .kt-blocks-info-box-learnmore{background:transparent;border-width:0px 0px 0px 0px;padding-top:4px;padding-right:8px;padding-bottom:4px;padding-left:8px;margin-top:10px;margin-right:0px;margin-bottom:10px;margin-left:0px;}<\/style>\n<div class=\"wp-block-kadence-infobox kt-info-box630_123b79-cd\"><span class=\"kt-blocks-info-box-link-wrap info-box-link kt-blocks-info-box-media-align-top kt-info-halign-center\"><div class=\"kt-blocks-info-box-media-container\"><div class=\"kt-blocks-info-box-media kt-info-media-animate-none\"><div class=\"kadence-info-box-icon-container kt-info-icon-animate-none\"><div class=\"kadence-info-box-icon-inner-container\"><span class=\"kb-svg-icon-wrap kb-svg-icon-fe_xCircle kt-info-svg-icon\"><svg viewBox=\"0 0 24 24\"  fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"  aria-hidden=\"true\"><circle cx=\"12\" cy=\"12\" r=\"10\"\/><line x1=\"15\" y1=\"9\" x2=\"9\" y2=\"15\"\/><line x1=\"9\" y1=\"9\" x2=\"15\" y2=\"15\"\/><\/svg><\/span><\/div><\/div><\/div><\/div><div class=\"kt-infobox-textcontent\"><h2 class=\"kt-blocks-info-box-title\">This study is closed to recruitment<\/h2><p class=\"kt-blocks-info-box-text\">To find out more about this research study, please contact:<br><a href=\"mailto:loth.sdcrn@nhs.scot\">loth.sdcrn@nhs.scot<\/a><br><strong>0131 537 3804<\/strong><\/p><\/div><\/span><\/div>\n\n\n\n<div class=\"wp-block-getwid-tabs\" data-active-tab=\"0\"><ul class=\"wp-block-getwid-tabs__nav-links\"><\/ul>\n<div class=\"wp-block-getwid-tabs__nav-link\"><span class=\"wp-block-getwid-tabs__title-wrapper\"><a href=\"#\"><span class=\"wp-block-getwid-tabs__title\">Study Staff<\/span><\/a><\/span><\/div><div class=\"wp-block-getwid-tabs__tab-content-wrapper\"><div class=\"wp-block-getwid-tabs__tab-content\">\n<p>Key Staff<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-large is-resized\"><a href=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/dr-gordon-duncan\/\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-1024x1024.jpg\" alt=\"\" class=\"wp-image-521\" style=\"aspect-ratio:1;object-fit:cover;width:auto;height:400px\" srcset=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-1024x1024.jpg 1024w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-300x300.jpg 300w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-150x150.jpg 150w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-768x768.jpg 768w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-1536x1536.jpg 1536w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-2048x2048.jpg 2048w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/Gordon-Duncan-2019-1140x1140.jpg 1140w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><figcaption class=\"wp-element-caption\"><span class=\"media-credit\">MAVERICK PHOTO AGENCY<\/span> NDN Principal Investigator: Dr Gordon Duncan<\/figcaption><\/figure>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-large is-resized\"><a href=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/jacqueline-kerr\/\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-1024x1024.jpg\" alt=\"\" class=\"wp-image-525\" style=\"aspect-ratio:1;object-fit:cover;width:auto;height:400px\" srcset=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-1024x1024.jpg 1024w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-300x300.jpg 300w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-150x150.jpg 150w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-768x768.jpg 768w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-1536x1536.jpg 1536w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-2048x2048.jpg 2048w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/01\/JK-Masters-graduation-photo-1140x1140.jpg 1140w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><figcaption class=\"wp-element-caption\">NDN Study Lead: Jacqueline Kerr<\/figcaption><\/figure>\n<\/div><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-getwid-tabs__nav-link\"><span class=\"wp-block-getwid-tabs__title-wrapper\"><a href=\"#\"><span class=\"wp-block-getwid-tabs__title\">Disease Area<\/span><\/a><\/span><\/div><div class=\"wp-block-getwid-tabs__tab-content-wrapper\"><div class=\"wp-block-getwid-tabs__tab-content\">\n<p>This study is looking at patients with Parkinson&#8217;s Disease.<\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-getwid-tabs__nav-link\"><span class=\"wp-block-getwid-tabs__title-wrapper\"><a href=\"#\"><span class=\"wp-block-getwid-tabs__title\">Funding and Sponsors<\/span><\/a><\/span><\/div><div class=\"wp-block-getwid-tabs__tab-content-wrapper\"><div class=\"wp-block-getwid-tabs__tab-content\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"320\" height=\"152\" src=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/CCTU_at_UCL_logo.png\" alt=\"\" class=\"wp-image-635\" srcset=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/CCTU_at_UCL_logo.png 320w, https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-content\/uploads\/sites\/111\/2023\/04\/CCTU_at_UCL_logo-300x143.png 300w\" sizes=\"auto, (max-width: 320px) 100vw, 320px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n<div id=\"contact\" class=\"wp-block-getwid-section minifooter2 gowide alignfull has-inner-blocks-gap-small getwid-section-content-full-width\"><div class=\"wp-block-getwid-section__wrapper getwid-padding-left-large getwid-padding-right-large getwid-padding-tablet-top-medium getwid-padding-tablet-bottom-large getwid-padding-tablet-left-medium getwid-padding-tablet-right-medium getwid-padding-mobile-top-medium getwid-padding-mobile-bottom-normal getwid-padding-mobile-left-medium getwid-padding-mobile-right-medium getwid-margin-left-none getwid-margin-right-none\" style=\"min-height:400px;padding-top:10px;padding-bottom:50px\"><div class=\"wp-block-getwid-section__inner-wrapper\"><div class=\"wp-block-getwid-section__background-holder\"><div class=\"wp-block-getwid-section__background\"><\/div><div class=\"wp-block-getwid-section__foreground\"><\/div><\/div><div class=\"wp-block-getwid-section__content\"><div class=\"wp-block-getwid-section__inner-content\">\n<div class=\"wp-block-group\" style=\"padding-bottom:0px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"footytext has-accent-colour-color has-text-color\"><strong>CONTACT INFORMATION<\/strong><\/p>\n\n\n\n<p>Neuroprogressive &amp;&nbsp;Dementia Research Network Office<br><br>Old Pharmacy Building<br>Western General Hospital<br>Edinburgh <br>EH4 2XU<\/p>\n\n\n\n<p>Email: <a href=\"mailto:loth.sdcrn@nhs.scot\">loth.sdcrn@nhs.scot<\/a><\/p>\n\n\n\n<p>Telephone: <strong>0131 537 3804<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"footytext has-accent-colour-color has-text-color\"><strong>ABOUT US<\/strong><\/p>\n\n\n\n<p>The NRS Neuroprogressive Disease and Dementia Network team in NHS Lothian conduct commercial and investigator led studies for: Alzheimer&#8217;s disease, Parkinson&#8217;s disease, Huntington&#8217;s disease, Motor Neurone Disease, dementia with Lewy bodies, Progressive Supranuclear Palsy and Multiple System Atrophy.<\/p>\n\n\n\n<p class=\"footytext has-accent-colour-color has-text-color\"><a href=\"https:\/\/youtube.com\" target=\"_blank\" rel=\"noopener\"><\/a><\/p>\n\n\n\n<p class=\"footytext\"><sub><strong>\u00a9 NHS LOTHIAN | YOUR SERVICE.<\/strong><\/sub><\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Phase 3 Trial of exenatide for Parkinson&rsquo;s disease Exenatide-PD3 is a clinical research trial for Parkinson&rsquo;s disease patients. It is a randomised, double-blind, placebo-controlled, parallel group phase 3 trial that will investigate the potential disease-modifying effects of Exenatide over two years. Parkinson&rsquo;s disease is the second most common neurodegenerative disease, and its prevalence is increasing.<\/p>\n","protected":false},"author":198,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[21,20],"class_list":["post-630","page","type-page","status-publish","hentry","category-previous-studies","category-studies"],"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"connordalby","author_link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/author\/connordalby\/"},"rttpg_comment":0,"rttpg_category":" <a href=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/category\/studies\/previous-studies\/\" rel=\"tag\">Previous Studies<\/a><a href=\"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/category\/studies\/\" rel=\"tag\">Studies<\/a>","rttpg_excerpt":"Phase 3 Trial of exenatide for Parkinson&rsquo;s disease Exenatide-PD3 is a clinical research trial for Parkinson&rsquo;s disease patients. It is a randomised, double-blind, placebo-controlled, parallel group phase 3 trial that will investigate the potential disease-modifying effects of Exenatide over two years. Parkinson&rsquo;s disease is the second most common neurodegenerative disease, and its prevalence is increasing.","_links":{"self":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/users\/198"}],"replies":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/comments?post=630"}],"version-history":[{"count":12,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/630\/revisions"}],"predecessor-version":[{"id":1848,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/630\/revisions\/1848"}],"wp:attachment":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/media?parent=630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/categories?post=630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}